Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice

M.C.T. van Zeijl; A.J.M. van den Eertwegh; M.W.J.M. Wouters; L.C. de Wreede; M.J.B. Aarts; F.W.P.J. van den Berkmortel; J.W.B. de Groot; G.A.P. Hospers; E. Kapiteijn; D. Piersma; R.S. van Rijn; K.P.M. Suijkerbuijk; A.J. ten Tije; A.A.M. van der Veldt; G. Vreugdenhil; J.J.M. van der Hoeven; J.B.A.G. Haanen

doi:10.1002/ijc.33800

Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice

M.C.T. van Zeijl, A.J.M. van den Eertwegh, M.W.J.M. Wouters, L.C. de Wreede, M.J.B. Aarts, F.W.P.J. van den Berkmortel, J.W.B. de Groot, G.A.P. Hospers, E. Kapiteijn, D. Piersma, R.S. van Rijn, K.P.M. Suijkerbuijk, A.J. ten Tije, A.A.M. van der Veldt, G. Vreugdenhil, J.J.M. van der Hoeven, J.B.A.G. Haanen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	317-326
Number of pages	10
Journal	International Journal of Cancer
Volume	150
Issue number	2
Early online date	2 Oct 2021
DOIs	https://doi.org/10.1002/ijc.33800
Publication status	Published - 15 Jan 2022

Keywords

advanced melanoma
anti-PD-1
discontinuation
immunotherapy
real-world
METASTATIC MELANOMA
SURVIVAL
PEMBROLIZUMAB
IPILIMUMAB

Access to Document

10.1002/ijc.33800Licence: CC BY-NC-ND

Cite this

van Zeijl, M. C. T., van den Eertwegh, A. J. M., Wouters, M. W. J. M., de Wreede, L. C., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., ten Tije, A. J., van der Veldt, A. A. M., Vreugdenhil, G., van der Hoeven, J. J. M., & Haanen, J. B. A. G. (2022). Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice. International Journal of Cancer, 150(2), 317-326. https://doi.org/10.1002/ijc.33800

van Zeijl, M.C.T. ; van den Eertwegh, A.J.M. ; Wouters, M.W.J.M. ; de Wreede, L.C. ; Aarts, M.J.B. ; van den Berkmortel, F.W.P.J. ; de Groot, J.W.B. ; Hospers, G.A.P. ; Kapiteijn, E. ; Piersma, D. ; van Rijn, R.S. ; Suijkerbuijk, K.P.M. ; ten Tije, A.J. ; van der Veldt, A.A.M. ; Vreugdenhil, G. ; van der Hoeven, J.J.M. ; Haanen, J.B.A.G. / Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice. In: International Journal of Cancer. 2022 ; Vol. 150, No. 2. pp. 317-326.

@article{a9949cc6ce3243dcaa7addea2397e7cd,

title = "Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice",

keywords = "advanced melanoma, anti-PD-1, discontinuation, immunotherapy, real-world, METASTATIC MELANOMA, SURVIVAL, PEMBROLIZUMAB, IPILIMUMAB",

author = "{van Zeijl}, M.C.T. and {van den Eertwegh}, A.J.M. and M.W.J.M. Wouters and {de Wreede}, L.C. and M.J.B. Aarts and {van den Berkmortel}, F.W.P.J. and {de Groot}, J.W.B. and G.A.P. Hospers and E. Kapiteijn and D. Piersma and {van Rijn}, R.S. and K.P.M. Suijkerbuijk and {ten Tije}, A.J. and {van der Veldt}, A.A.M. and G. Vreugdenhil and {van der Hoeven}, J.J.M. and J.B.A.G. Haanen",

year = "2022",

month = jan,

day = "15",

doi = "10.1002/ijc.33800",

language = "English",

volume = "150",

pages = "317--326",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "Wiley",

number = "2",

}

van Zeijl, MCT, van den Eertwegh, AJM, Wouters, MWJM, de Wreede, LC, Aarts, MJB, van den Berkmortel, FWPJ, de Groot, JWB, Hospers, GAP, Kapiteijn, E, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, ten Tije, AJ, van der Veldt, AAM, Vreugdenhil, G, van der Hoeven, JJM & Haanen, JBAG 2022, 'Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice', International Journal of Cancer, vol. 150, no. 2, pp. 317-326. https://doi.org/10.1002/ijc.33800

Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice. / van Zeijl, M.C.T.; van den Eertwegh, A.J.M.; Wouters, M.W.J.M.; de Wreede, L.C.; Aarts, M.J.B.; van den Berkmortel, F.W.P.J.; de Groot, J.W.B.; Hospers, G.A.P.; Kapiteijn, E.; Piersma, D.; van Rijn, R.S.; Suijkerbuijk, K.P.M.; ten Tije, A.J.; van der Veldt, A.A.M.; Vreugdenhil, G.; van der Hoeven, J.J.M.; Haanen, J.B.A.G.

In: International Journal of Cancer, Vol. 150, No. 2, 15.01.2022, p. 317-326.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice

AU - van Zeijl, M.C.T.

AU - van den Eertwegh, A.J.M.

AU - Wouters, M.W.J.M.

AU - de Wreede, L.C.

AU - Aarts, M.J.B.

AU - van den Berkmortel, F.W.P.J.

AU - de Groot, J.W.B.

AU - Hospers, G.A.P.

AU - Kapiteijn, E.

AU - Piersma, D.

AU - van Rijn, R.S.

AU - Suijkerbuijk, K.P.M.

AU - ten Tije, A.J.

AU - van der Veldt, A.A.M.

AU - Vreugdenhil, G.

AU - van der Hoeven, J.J.M.

AU - Haanen, J.B.A.G.

PY - 2022/1/15

Y1 - 2022/1/15

KW - advanced melanoma

KW - anti-PD-1

KW - discontinuation

KW - immunotherapy

KW - real-world

KW - METASTATIC MELANOMA

KW - SURVIVAL

KW - PEMBROLIZUMAB

KW - IPILIMUMAB

U2 - 10.1002/ijc.33800

DO - 10.1002/ijc.33800

M3 - Article

C2 - 34520567

VL - 150

SP - 317

EP - 326

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -